Co-Diagnostics develops test for mutated COVID-19 strain in U.K.

By LabPulse.com staff writers

December 22, 2020 -- Co-Diagnostics announced that it has developed a molecular test for mutations that have been associated with a new variant of the coronavirus that has been causing alarm.

The company said in a statement that its polymerase chain reaction (PCR) test screens for the variant under investigation (VUI) circulating in the U.K. and causing much alarm -- VUI 202012/01. The emergence of a SARS-CoV-2 strain that appears to be more easily transmitted has led to tighter lockdowns in the U.K. and global travel bans for residents.

The performance of the company's commercially available COVID-19 tests is not thought to be adversely affected by the new strain, said Co-Diagnostics, which is based in Salt Lake City.


Copyright © 2020 LabPulse.com
 

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?